NCT00000871View on ClinicalTrials.gov

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

Not specified

Study Completion Date

January 31, 2000

Conditions
HIV Infections
Interventions
BIOLOGICAL

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1

BIOLOGICAL

MN rgp120/HIV-1 and A244 rgp120/HIV-1

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (18)

10016

NY Blood Ctr. HIVNET, New York

NY Univ. Med. Ctr. HIVNET, New York

14642

Univ. of Rochester AVEG, Rochester

19104

Univ. of Pennsylvania HIVNET, Philadelphia

21205

JHU AVEG, Baltimore

35294

UAB AVEG, Birmingham

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

60612

Cook County Hospital HIVNET, Chicago

Unknown

Public Health Enterprises Foundation, Inc. HIVNET, San Francisco

Denver Dept. of Health HIVNET, Denver

Denver Public Health CRS, Denver

Univ. of Illinois at Chicago HIVNET, Chicago

St. Louis Univ. School of Medicine AVEG, St Louis

UW - Seattle AVEG, Seattle

Uw Hivnet, Seattle

02115

Fenway Community Health Center HIVNET, Boston

02906

Memorial Hosp. of Rhode Island HIVNET, Providence

The Miriam Hosp. HIVNET, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH